Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

NCT04776018 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04776018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Terminated
Start date
April 20, 2021
Completion date
November 9, 2023
Enrollment
27 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma (rrmm)